Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis
Mehmet Kanbay, Laura Țăpoi, Carina Ureche, et al.
International Urology and Nephrology (2021) Vol. 54, Iss. 4, pp. 827-841
Closed Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Bo Xu, Shaoqian Li, Bo-Kyeong Kang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 116
Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia
Milton Packer
American Journal of Nephrology (2023) Vol. 55, Iss. 2, pp. 255-259
Open Access | Times Cited: 19
Cardioprotective Effect of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients: A Multicenter Propensity Score Matched Study
Jeong‐Hoon Lim, Soie Kwon, Yu Jin Seo, et al.
Kidney International Reports (2024) Vol. 9, Iss. 8, pp. 2474-2483
Open Access | Times Cited: 7
SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study
Anja Schork, Marie-Luise Eberbach, Bernhard N. Bohnert, et al.
Kidney & Blood Pressure Research (2024)
Open Access | Times Cited: 6
Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
Siarhei A. Dabravolski, Alexander D. Zhuravlev, Andrey G. Kartuesov, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5371-5371
Open Access | Times Cited: 23
An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis
Dóra Balogh, László Wagner, Andrea Fekete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7789-7789
Open Access | Times Cited: 15
SGLT2 inhibitors, intrarenal hypoxia and the diabetic kidney: insights into pathophysiological concepts and current evidence
Georgios S. Papaetis
Archives of Medical Science - Atherosclerotic Diseases (2024) Vol. 8, Iss. 1, pp. 155-168
Open Access | Times Cited: 3
Effect of SGLT2 inhibitors on anemia and their possible clinical implications
Aleix Cases, Secundino Cigarrán, José Luis Górriz, et al.
Nefrología (English Edition) (2024) Vol. 44, Iss. 2, pp. 165-172
Open Access | Times Cited: 3
Sodium-glucose co-transporter inhibitors for APOL1 kidney disease: A call for studies
Barış Afşar, Rengin Elsürer Afşar, Yasar Caliskan, et al.
International Urology and Nephrology (2025)
Closed Access
SGLT2 Inhibitors Increase Hemoglobin and Hematocrit Levels in Patients With Chronic Kidney Disease: A Systematic Review and Meta‐Analysis
Hye Duck Choi, Seung Woo Lee
Journal of Clinical Pharmacy and Therapeutics (2025) Vol. 2025, Iss. 1
Open Access
The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest
Dimitrios Patoulias, Nikolaos Fragakis, Manfredi Rizzo
Life (2022) Vol. 12, Iss. 12, pp. 2062-2062
Open Access | Times Cited: 15
Sodium–Glucose Transporter 2 (SGLT2) Inhibitors and Iron Deficiency in Heart Failure and Chronic Kidney Disease: A Literature Review
Maria Tziastoudi, Georgios Pissas, Spyridon Golfinopoulos, et al.
Life (2023) Vol. 13, Iss. 12, pp. 2338-2338
Open Access | Times Cited: 8
Heterogeneous afferent arteriolopathy: a key concept for understanding blood pressure–dependent renal damage
Kentaro Kohagura, Ryo Zamami, Nanako Oshiro, et al.
Hypertension Research (2024)
Open Access | Times Cited: 3
Sodium–glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms
Barış Afşar, Rengin Elsürer Afşar
Pharmacological Reports (2022) Vol. 75, Iss. 1, pp. 44-68
Closed Access | Times Cited: 13
Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study
Alessandro Maria Berton, Mirko Parasiliti‐Caprino, Nunzia Prencipe, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 7
Efecto de los inhibidores del cotransportador sodio-glucosa tipo 2 sobre la anemia: posibles implicaciones clínicas
Aleix Cases, Secundino Cigarrán, José Luis Górriz, et al.
Nefrología (2023) Vol. 44, Iss. 2, pp. 165-172
Open Access | Times Cited: 7
Autonomic Nervous System: A Therapeutic Target for Cardiac End-Organ Damage in Hypertension
Lisa A. Gottlieb, Felix Mahfoud, Stavros Stavrakis, et al.
Hypertension (2024) Vol. 81, Iss. 10, pp. 2027-2037
Open Access | Times Cited: 2
New Approaches to Diabetic Nephropathy from Bed to Bench
Jun-Li Tsai, Cheng‐Hsu Chen, Ming‐Ju Wu, et al.
Biomedicines (2022) Vol. 10, Iss. 4, pp. 876-876
Open Access | Times Cited: 8
Drug Safety Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Comorbid Patients by Review of Systemic Extraglycemic Effects
Mohammad Belal Omari, Shafiqullah Naseri, Abdul Jalil Hassan
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 1131-1141
Open Access | Times Cited: 1
SGLT-2 inhibitors in chronic peritoneal dialysis patients: a follow-up study
Jia‐Wen Lai, Charles C. N. Wang, Che‐Yi Chou
BMC Nephrology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases
Satoshi Yamasaki, Takahiko Horiuchi
Hematology Reports (2023) Vol. 15, Iss. 1, pp. 180-187
Open Access | Times Cited: 2
Cardio-renoprotective effects of SGLT2 inhibitors—the role of anaemia correction
Francesco Locatelli, Lucia Del Vecchio
Nephrology Dialysis Transplantation (2024) Vol. 39, Iss. 6, pp. 904-906
Open Access
Prevalence and characteristics of anemia in patients with diabetes mellitus aged 50 or older in health unit area of Cadiz (Spain)
Alfredo Michán‐Doña, E. Jiménez-Varo, M. Escribano-Cobalea, et al.
Revista Clínica Española (English Edition) (2024) Vol. 224, Iss. 7, pp. 457-465
Closed Access
Prevalencia y características de la anemia en personas con diabetes mellitus de 50 años o más en un área sanitaria de Cádiz (España)
Alfredo Michán‐Doña, E. Jiménez-Varo, M. Escribano-Cobalea, et al.
Revista Clínica Española (2024) Vol. 224, Iss. 7, pp. 457-465
Closed Access
Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection
Shibing Tao, S. Guo, Nanwei Tong
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2024) Vol. 44, Iss. 8, pp. 642-657
Closed Access
Page 1 - Next Page

Scroll to top